Press release
SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China,
About this update from Sinovac Biotech, Ltd.
[{"type":"text","content":" BEIJING--(BUSINESS WIRE)--\nSinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile (PI Dr. Pablo González). Study results will provide scientific evidence to support SINOVAC’s influenza vaccine immunogenicity and protection capacity.\n\nThis clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above. In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVAC’s inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile. Children aged between 3 and 8 of both groups who haven’t received any influenza vaccine will receive 2 doses of influenza vaccine. All of the participants will be observed for 28 days following the completed inoculation to evaluate vaccine safety. The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVAC’s quadrivalent influenza vaccine.\n\nAbout SINOVAC\n\nSinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.\n\nSINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.\n\nThe COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.\n\nSINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program....